Entering text into the input field will update the search result below

Bristol gains approval of first-in-class immunotherapy for melanoma Opdualag

Mar. 19, 2022 1:10 PM ETBristol-Myers Squibb Company (BMY) StockBy: Jonathan Block, SA News Editor15 Comments

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

  • The U.S. FDA has approved Bristol-Myers Squibb's (NYSE:BMY) Opdualag, a combination of Opdivo (nivolumab) and the novel agent relatlimab, for unresectable or metastatic melanoma.
  • Opdivo is a PD-1 inhibitor with many cancer indications while relatlimab is a novel LAG-3 blocker.
  • In the phase 2/3 RELATIVITY-047 trial, Opdualag more than doubled median progression-free survival compared to Opdivo alone -- 10.1 months vs. 4.6 months.
  • The approval is for adults and children 12 and older.
  • Bristol (BMY) has previously stated Opdualag could reach annual sales of $4B by 2029.
  • Check out why Seeking Alpha contributor Edmund Ingham says that Bristol (BMY) is a buy.

Recommended For You

About BMY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BMY--
Bristol-Myers Squibb Company